Mucopolysaccharidosis Type IVA: Extracellular Matrix Biomarkers in Cardiovascular Disease

Mucopolysaccharidosis Type IVA: Extracellular Matrix Biomarkers in Cardiovascular Disease

Cardiovascular disease (CVD) in Mucopolysaccharidosis Type IVA (Morquio A), signified by valvular disease and cardiac hypertrophy, is the second leading cause of death and remains untouched by current therapies. Enzyme replacement therapy (ERT) is the gold-standard treatment for MPS disorders includ...

Full description

Bibliographic Details
Main Authors: Brittany Montavon, Linda E. Winter, Qi Gan, Amirhossein Arasteh, Adriana M. Montaño
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Morquio A
MPS IVA
cardiovascular disease
biomarkers
cathepsin S
elastin
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.829111/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.829111/full

Similar Items